To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the ...

Publication marks the first time in nearly two decades that The New England Journal of Medicine has published clinical data on standalone real-time continuous glucose monitoring (CGM) technology, ...

We have excluded third-party attorney’s fees, costs, and expenses incurred by Dexcom exclusively in connection with Dexcom’s patent infringement litigation against Abbott Diabetes Care, Inc., as ...

Partnership will enable two-way data flow between Dexcom glucose biosensors and apps and Oura Ring and the Oura App, providing a first-of-its-kind metabolic health management experience Co-marketing ...

For the three and nine months ended September 30, 2025, business transition and other significant items are primarily related to workforce reduction costs associated with organizational realignment ...

For the three months ended December 31, 2025, business transition and other significant items are primarily related to rent for vacated office space in San Diego, California. For the twelve months ...

(2) For the three and twelve months ended December 31, 2023, business transition and related costs are primarily related to rent for vacated office space in San Diego, California. For the three months ...

Mr. Leach begins his inaugural year as CEO with speaking engagements at CES 2026 and the 44 th annual J.P. Morgan Healthcare Conference A completely reimagined Stelo app experience will launch this ...

At Aspen Ideas: Health, Dexcom announced regulatory milestones, including pediatric clearance for Stelo, further advancing access to glucose biosensing in the United States. The company also announced ...

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM) today announced key updates to its governance structure in conjunction with its upcoming 2026 Investor Day presentation that outlines a ...